• Adocia will present AdoXLong preclinical data at ObesityWeek in Washington on November 14, 2026.
• The platform aims to replace weekly injections for diabetes and obesity with once-monthly dosing.
• Positive preliminary laboratory results with AdoXL Retatrutide support the platform's potential application across multiple peptide treatments.
• Development will continue toward clinical testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109907087) on November 09, 2026, and is solely responsible for the information contained therein.